Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 14/20 | 0.59 |
| ▸ | HSP90AB1 | P08238 | 6/20 | 0.36 |
| ▸ | ESR1 | P03372 | 4/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4939661 | 0.92 | HSP90AA1 (0.59) | HSP90AA1HSP90AB1ESR1TP53APLNR | |
| SCHEMBL4935357 | 0.91 | HSP90AA1 (0.72) | HSP90AA1ESR1TP53APLNR | |
| SCHEMBL645464 | 0.90 | HSP90AA1 (0.58) | HSP90AA1ESR1TP53APLNR | |
| SCHEMBL645783 | 0.87 | HSP90AA1 (0.46) | HSP90AA1HSP90AB1TP53 | |
| SCHEMBL646952 | 0.85 | HSP90AA1 (0.44) | HSP90AA1HSP90AB1 | |
| SCHEMBL4941779 | 0.84 | HSP90AA1 (0.52) | HSP90AA1ESR1TP53APLNR | |
| SCHEMBL646963 | 0.84 | HSP90AA1 (0.43) | HSP90AA1HSP90AB1 | |
| SCHEMBL645798 | 0.84 | HSP90AA1 (0.51) | HSP90AA1HSP90AB1 | |
| SCHEMBL646605 | 0.84 | HSP90AA1 (0.49) | HSP90AA1HSP90AB1 | |
| SCHEMBL646674 | 0.84 | HSP90AA1 (0.43) | HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8618285-B2 | Triazole derivatives | MERCK PATENT GMBH (DE) | 2013-12-31 | — | — | US | claimed |
| EP-1853570-B1 | HSP90-INHIBITING TRIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-10-24 | — | — | EP | claimed |
| US-20080182857-A1 | Triazole Derivatives | MERCK PATENT GMBH (DE) | 2008-07-31 | — | — | US | claimed |
| US-8618285-B2 | Triazole derivatives | MERCK PATENT GMBH (DE) | 2013-12-31 | — | — | US | disclosed |
| EP-1853570-B1 | HSP90-INHIBITING TRIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-10-24 | — | — | EP | disclosed |
| US-20080182857-A1 | Triazole Derivatives | MERCK PATENT GMBH (DE) | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182857-A1 | Triazole Derivatives | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AA1 2/4885HSP90AB1 1/4885ESR1 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.